Back to Journals » Clinical Ophthalmology » Volume 13

Outcome Of MicroPulse® Transscleral Photocoagulation In Different Types Of Glaucoma

Authors Al Habash A, AlAhmadi AS

Received 8 August 2019

Accepted for publication 5 November 2019

Published 2 December 2019 Volume 2019:13 Pages 2353—2360

DOI https://doi.org/10.2147/OPTH.S226554

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Ahmed Al Habash,1 Adel Salah AlAhmadi2

1Department of Ophthalmology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia; 2Ministry of Health, Madinah, Saudi Arabia

Correspondence: Ahmed Al Habash
Department of Ophthalmology, King Fahd Hospital of the University, Imam Abdulrahman Bin Faisal University, Dammam, Saudi Arabia
Email ahmedalhabash@gmail.com

Purpose: To evaluate the safety and efficacy of MicroPulse® transscleral cyclophotocoagulation (μP-TSCPC) up to 24-months follow-up using a standardized fixed protocol in patients with various types of glaucoma.
Methods: Prospective, nonrandomized, non-comparative interventional case series of μP-TSCPC performed by a single glaucoma surgeon at tertiary hospitals between May 2017 and May 2019.
Results: A total of 71 eyes of 68 patients (39 males, 29 females) aged 60.0 years (13–89 years) were treated with μP-TSCPC. The most common diagnosis was neovascular glaucoma. The safety index of corrected distance visual acuity (CDVA) was 1.0, i.e. there was no significant change in CDVA postoperatively compared to baseline CDVA. The median baseline IOP was 35.0 mmHg (21.0–70.0 mmHg), which was reduced to 16 mmHg (8–32 mmHg) at 12 months/last follow-up postoperatively (p<0.001, Wilcoxon signed-rank test). The median reduction in IOP was 52% (0.0–89%) at 12 months/last follow-up postoperatively compared to baseline. The median number of medications was 5 (3–5) at baseline compared to 4 (2–4) at 12 months/last follow-up postoperatively (p<0.001, Wilcoxon signed-rank test). The percent of eyes treated with systemic glaucoma medication was 62% (44) at baseline compared to 0% (0) at 12 months/last follow-up postoperatively. The postoperative surgical success of 90%, 91.4%, and 95.7% at 2 weeks, 3 months, and 6 months respectively then remains unchanged. No significant adverse events or complications were observed.
Conclusion: μP-TSCPC demonstrated good efficacy and safety profiles with minimal vision-threatening complications in treating a variety of glaucoma types.

Keywords: glaucoma, ciliary body, transscleral cyclophotocoagulation, MicroPulse diode laser
 

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]